Müller-Hülsbeck Stefan, Frahm Christian, Behm Charlotte, Schäfer Phillip Jobst, Bolte Hendrik, Heller Martin, Jahnke Thomas
Department of Radiology, University Hospital Schleswig-Holstein, Campus Kiel, Christian-Albrechts-University Kiel, Arnold-Heller-Strasse 9, 24105 Kiel, Germany.
J Vasc Interv Radiol. 2005 Jul;16(7):963-71. doi: 10.1097/01.RVI.0000163013.46098.D4.
To determine feasibility, safety, and midterm patency of a monorail balloon stent device for the treatment of renal artery stenosis (RAS).
During a period of 30 months, 47 patients (with severe hypertension, n=45; renal insufficiency, n=20) with 50 cases of RAS and indications for stent implantation (calcified ostial lesion, n=41; insufficient percutaneous transluminal angioplasty, n=6; dissection, n=3) were enrolled into the prospective evaluation. After predilation, 59 stents (Rx-Herculink 4 mm, n=2; 5 mm, n=19; 6 mm, n=35; 7 mm, n=3) were implanted under manometer control with use of the long-sheath technique (5 F; 6 F for 7-mm stents) via a femoral (n=44) or transbrachial approach (n=6). Parameters of hypertension and renal insufficiency were determined before and after the procedure and for a maximum of 18 months. Restenosis rate was determined with color duplex ultrasonography.
Renal artery stent placement (mean diameter, 5.7 mm; mean length, 16 mm) was technically successful in all cases (100%). Mean blood pressure and serum creatinine level decreased from 177/93 mm Hg to 145/78 mm Hg and from 1.8 mg/dL to 1.5 mg/dL, respectively. Within 48 hours after the implantation, acute occlusions occurred in two patients, supposedly triggered by cholesterol embolization. Primary and primary assisted patency rates were 87% and 92% at 6 months and 75% and 84% at 18 months.
Renal artery stent placement with the rapid-exchange monorail system is a safe procedure with promising patency rates. In combination with the long-sheath technique, adequate control of stent deployment is guaranteed during the entire intervention. The low profile of the device facilitates the use of small sheaths (5 F) to minimize access-site complications.
确定单轨球囊支架装置治疗肾动脉狭窄(RAS)的可行性、安全性及中期通畅率。
在30个月的时间里,47例患者(重度高血压45例;肾功能不全20例)共50处肾动脉狭窄且有支架植入指征(钙化开口病变41处;经皮腔内血管成形术效果不佳6处;夹层3处)纳入前瞻性评估。预扩张后,采用长鞘技术(5F;7mm支架用6F)经股动脉(44例)或经肱动脉途径(6例),在压力计控制下植入59枚支架(Rx-Herculink 4mm,2枚;5mm,19枚;6mm,35枚;7mm,3枚)。在手术前后及最长18个月内测定高血压和肾功能不全参数。用彩色双功超声测定再狭窄率。
肾动脉支架置入(平均直径5.7mm;平均长度16mm)在所有病例中技术上均成功(100%)。平均血压和血清肌酐水平分别从177/93mmHg降至145/78mmHg,从1.8mg/dL降至1.5mg/dL)。植入后48小时内,2例患者发生急性闭塞,推测由胆固醇栓塞引发。6个月时的初始通畅率和初始辅助通畅率分别为87%和92%,18个月时分别为75%和84%。
使用快速交换单轨系统进行肾动脉支架置入是一种安全的手术,通畅率前景良好。结合长鞘技术,在整个干预过程中能保证对支架展开的充分控制。该装置外形小巧,便于使用小鞘管(5F)以尽量减少穿刺部位并发症。